There is concern that drug-resistant tuberculosis is increasing and may be concentrated among HIV-positive patients. Little information is available from developing countries, where surveillance studies are often unable to distinguish resistance in previously untreated patients (initial resistance) from resistance acquired following drug therapy, and where information on the HIV status of the patients is rare. Initial resistance patterns reflect the strains being transmitted in the community. We have studied patterns of resistance in northern Malawi, where the Lepra Evaluation Project has been collecting data on drug resistance since 1986. Initial drug sensitivity results were available for 373 new cases of tuberculosis. Initial resistance to at least one drug was found in 44 of these patients (11.8%, 95% CI 8.5-15.1): 13 were resistant to streptomycin alone, 13 to isoniazid alone, and 17 to more than one drug. Only 3 patients showed initial rifampicin resistance-1 in isolation, 1 in combination with streptomycin, and 1 with triple resistance. Drug resistance was not related to age, sex, or HIV status of the patient and there was no evidence of any increase over the period studied. There was no evidence of geographic clustering of the resistant strains, or of any increased risk of resistant strains in households with previous tuberculosis cases. Acquired resistance during follow-up was found in 5 of 329 patients with documented initially fully sensitive strains. 5 patients with initial resistance seemed to show reversion to sensitivity. The absence of an increase in drug resistance, despite an increase in tuberculosis cases over the period, is encouraging for the control programme. It emphasises the need to collect information from many areas before assuming that increases in antituberculosis drug resistance are occurring worldwide.

During a large epidemiologic study in the Karonga District of northern Malawi, serum samples from 139 patients with incident leprosy, 124 with newly diagnosed leprosy, 277 patients with incident tuberculosis, and 2296 controls were tested for antibodies to human immunodeficiency virus, Sera were tested according to a four-test protocol using two ELISAs and two particle agglutination assays. Overall, 188 samples were considered positive, 2634 were considered negative, and 14 were indeterminate. All 18 available positive specimens from leprosy patients, a random sample of 14 positive specimens from tuberculosis patients, and 15 positive specimens from controls were tested by Western blot. There was no evidence of substantial numbers of ELISA false-positives in any patient group or among controls.

Testing for antibodies to human immunodeficiency virus (HIV) in urine may be of use in epidemiological studies. We collected 336 paired urine and serum samples from subjects in Karonga District, northern Malawi: 86 (25.6%) of the serum samples were HIV positive. Serum results were compared with those from immunoglobulin (Ig) G antibody-capture particle adherence tests (GACPAT) and IgG antibody-capture enzyme-linked immunosorbent assay (GACELISA) on the corresponding urine samples performed independently in 2 laboratories. The minimum observed relative sensitivity and specificity of GACPAT were 96.5% and 98.8% respectively; the specificity could be raised by using a protocol involving re-testing of reactive samples to determine end-point titre. For GACELISA, the observed relative sensitivity and specificity were 98.8% and 99.2% respectively. Such assays may be useful either as a primary screen in populations where urine samples are considerably easier to obtain than serum samples, or as an alternative test for individuals unwilling to provide a serum sample.